Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Phathom Pharmaceuticals Q2 Adj. EPS $(0.79) Beats $(0.98) Estimate, Sales $39.503M Beat $36.383M Estimate

Author: Benzinga Newsdesk | August 07, 2025 06:01am
Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(0.98) by 19.39 percent. This is a 36.8 percent increase over losses of $(1.25) per share from the same period last year. The company reported quarterly sales of $39.503 million which beat the analyst consensus estimate of $36.383 million by 8.58 percent. This is a 439.36 percent increase over sales of $7.324 million the same period last year.

Posted In: PHAT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist